September 16, 2014 6:05 PM ET

Biotechnology

Company Overview of HemoShear, LLC

Company Overview

HemoShear, LLC, a biotechnology research company, develops and creates human-relevant systems that replicate the biology of organ systems and diseases in drug discovery and development. It conducts various experimental programs using human or animal primary cells; recreates in vivo hemodynamic conditions; cultures multiple cell types together to restore native biology; uses primary cells in physiologically accurate media conditions; creates physiologically relevant systems for understanding human responses in healthy and disease states; and provides human vascular systems, including artery systems, arteriole and microvascular systems, advanced inflammatory systems, atherosclerosis-prone cond...

1115 5th Street SW

Charlottesville, VA 22902

United States

Founded in 2008

Phone:

434-872-0196

Fax:

434-872-0199

Key Executives for HemoShear, LLC

Chairman and Chief Executive Officer
Age: 62
Vice Chairman
Vice President of Operations
Compensation as of Fiscal Year 2014.

HemoShear, LLC Key Developments

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: Jun-24-2014, Vincent Aurentz, Chief Business Officer. Jun-25-2014, Brian R. Wamhoff, Co-Founder, Vice President of Research & Development and Director.

HemoShear, LLC Enters into R&D Collaboration with Medivir AB

HemoShear, LLC announced research collaboration with Medivir AB. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects of drug candidates on liver tissue using the Company's first-in-class human liver system. The HemoShear human liver system accurately replicates in vivo physiological conditions, enabling a more precise and definitive assessment of targets and drug candidates, drug-induced changes in biology and pharmacological responses. The collaboration with Medivir will also leverage and contribute to the set of drug exposure data HemoShear is creating as part of an ongoing program funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of NIH.

HemoShear, LLC to Develop Human Cancer Models to Improve Industry Success Rates in New Anticancer Drug Development

Small Business Innovation Research contract awarded to HemoShear, LLC by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). HemoShear's contract with the National Cancer Institute will support the development of human cell-based systems that accurately replicate the biology of lung and pancreatic tumors, two of the deadliest groups of tumors. HemoShear's success in this initial stage of tumor system development will lead to development of other cancer tumor systems, to systems that replicate metastasis and potentially to new treatments for patient-specific tumors.

Similar Private Companies By Industry

Company Name Region
Moderna Therapeutics, Inc. United States
American Centrality Group, Inc. United States
Edenspace Systems Corporation United States
Advanced Pain Remedies, Inc. United States
Spinnaker Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 7, 2014
--
Private Placement
October 20, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HemoShear, LLC, please visit www.hemoshear.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.